Prevention of Hepatocellular Carcinoma

Schütte, Kerstin; Balbisi, Fathi; Malfertheiner, Peter

doi:10.1159/000446680

Cited by 22 publications

(27 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 It is theoretically an excellent method for cancer prevention. Primary prevention of hepatocarcinogenesis could be accomplished most effectively by universal immunization against the hepatotropic viruses.…”

Section: Primary Preventionmentioning

confidence: 99%

“…12 Along these lines, inhibiting the replication of HBV or completely eliminating HCV from the body could prevent hepatocarcinogenesis in patients with viral hepatitis. 9,[20][21][22] Several clinical trials and observational studies have reported the beneficial effects of antiviral treatment for preventing HCC through persistent viral suppression.…”

Section: Secondary Preventionmentioning

confidence: 99%

“…2,12 Cirrhosis is a precancerous condition. 28 Thus, surveillance at regular intervals is recommended in all patients with cirrhosis to detect HCC at an early stage.…”

Section: Tertiary Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

Etık

Suna²,

Boyacioglu³

2017

Exp Clin Transplant

View full text Add to dashboard Cite

More than 600 000 people die from hepatocellular carcinoma each year. Worldwide, research on the disease needs to be intensified in both the medical and pharmaceutical fields, with a focus on providing help to geographic areas where resources are limited. Treatment approaches depend on the stage of the disease at diagnosis and on access to complex treatment regimens. However, advanced disease is not curable, and treating these patients is expensive and only marginally effective for increasing qualityadjusted life-years. Although the Milan criteria are often used to determine which patients will benefit from liver transplantation, many centers have their own criteria for patient selection. According to criteria developed by Başkent University in Ankara, Turkey, patients with hepatocellular carcinoma and a cirrhotic liver but without extrahepatic disease should be candidates for liver transplant when possible, and living-donor liver transplant should be considered as an alternative rescue therapy for many of these patients. Tumor size and number should not be the sole criteria for excluding liver transplant. Although significant vascular invasion and extrahepatic dissemination definitely indicate major tumor dissemination, until sensitive tests for measuring circulating tumor cells are developed, we continue to recommend liver transplant regardless of tumor size and number. Various locoregional therapies for hepatocellular carcinoma are used before transplant to prevent tumor progression and to decrease the risk of recurrence after transplant. In turn, response to locoregional therapy to decrease tumor stage in hepatocellular carcinoma may be an indicator of tumor behavior and may determine a patient's selection for liver transplant. The delivery of healthcare services for hepatocellular carcinoma could be improved by developing centers of excellence. Concentrating medical care in this way can lead to an increased level of expertise so that resections are performed by surgeons who understand liver disease and the limitations of these and other procedures.

show abstract

Section: Primary Preventionmentioning

confidence: 99%

Section: Secondary Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

Etık

Suna²,

Boyacioglu³

2017

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…However, due to the insidious early symptoms, rapid tumor progression, and controversial strategies of combining various therapies, more than 70% of advanced HCC patients do not improve survival with the abovementioned therapies . Identifying the intracellular molecular alterations involved in HCC development and progression is crucial for understanding the mechanisms of hepatocarcinogenesis and for improving the clinical outcomes of HCC patients …”

Section: Introductionmentioning

confidence: 99%

“…[6][7][8] Identifying the intracellular molecular alterations involved in HCC development and progression is crucial for understanding the mechanisms of hepatocarcinogenesis and for improving the clinical outcomes of HCC patients. 9,10 One of the mechanisms of tumorigenesis is the abundant accumulation of intracellular DNA lesions and mutations. How mammalian cells respond to various types of DNA damage is a critical determinant of whether an individual develops a tumor.…”

mentioning

confidence: 99%

HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma

Zhou

Zhao

Chen

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

The HUS1 checkpoint clamp component (HUS1), which is a member of an evolutionarily conserved, genotoxin-activated checkpoint complex (Rad9-Rad1-Hus1 [9-1-1] complex), is involved in cell cycle arrest and DNA repair in response to DNA damage. We conducted this study to investigate the biological significances of HUS1 expression in hepatocellular carcinoma (HCC) development. The mRNA and protein expression levels of HUS1 were determined using Real-time PCR and Western blot, respectively. One hundered and twenty four paraffin sections from HCC tissues were analyzed by immunohistochemistry to assess the association between HUS1 expression and clinicopathological characteristics of patients. The Kaplan-Meier method was performed to calculate the OS and RFS curves. Cell proliferation and colony formation assays, cell migration and invasion assays and cell cycle assays were used to determine the suppressor role of HUS1 in vitro. A mouse model was used to determine the effect of HUS1 on tumorigenesis. The expression of HUS1 was significantly decreased in HCC cell lines and tissues, and low HUS1 expression was associated with poor prognosis of HCC patients. Upregulation of HUS1 expression inhibited the cell proliferation, colony formation, migration, and invasion, as well as arrested cell cycle at G0/G1 in HCC cells in vitro. Moreover, sufficient HUS1 expression inhibited the tumor growth in nude mice. Our study revealed for the first time that HUS1 is a potential tumor suppressor that might produce an antitumor effect in human HCC. Furthermore, HUS1 may serve as a prognostic indicator and could be used for therapeutic application in HCC patients.

show abstract